A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects

NCT00000713 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Ampligen

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)